ARBs Have the Milder Side-Effect Profile
For antihypertensive therapy, ARBs (angiotensin-II-receptor blockers) have a substantially milder side-effect profile compared to ACE inhibitors, primarily due to significantly lower rates of cough and angioedema.
Key Side-Effect Differences
ARBs Cause Fewer Adverse Events
The most compelling evidence comes from direct comparisons showing ARBs consistently demonstrate superior tolerability:
- ARBs reduce withdrawal rates due to adverse events by 17% compared to ACE inhibitors (RR 0.83; 95% CI 0.74-0.93), with an absolute risk reduction of 1.8% over approximately 4 years 1
- This translates to 1 fewer patient discontinuing therapy for every 55 patients treated with an ARB instead of an ACE inhibitor 1
Specific Side Effects Where ARBs Excel
Cough: The most clinically significant difference is cough incidence. ACE inhibitors cause cough in up to 20% of patients due to kininase inhibition and bradykinin accumulation 2, 3. ARBs do not inhibit kininase and are associated with a much lower incidence of cough 2, 3. This is the primary reason patients switch from ACE inhibitors to ARBs in clinical practice.
Angioedema: While rare (<1% with ACE inhibitors), angioedema is more common with ACE inhibitors than ARBs 3. Angioedema occurs more frequently in Black patients and women on ACE inhibitors 3. ARBs carry a substantially lower risk of angioedema 2, 3, though caution is still advised as some patients who developed angioedema on ACE inhibitors may also develop it with ARBs 2, 3.
Clinical Implications
When to Choose ARBs Over ACE Inhibitors
ARBs are specifically recommended as first-line therapy for patients who:
- Cannot tolerate ACE inhibitors due to cough 2, 3
- Have experienced angioedema on ACE inhibitors (with caution) 2, 3
- Require equivalent cardiovascular protection with better tolerability 4
Equivalent Efficacy Profile
Multiple guidelines confirm that ARBs and ACE inhibitors demonstrate equivalent efficacy for:
- Blood pressure reduction 4, 1
- All-cause mortality 4, 1
- Cardiovascular mortality 4, 1
- Myocardial infarction 4, 1
- Heart failure outcomes 4, 1
- Stroke prevention 4, 1
- End-stage renal disease 4
The 2017 ACC/AHA guidelines explicitly state that ARBs produce "hemodynamic, neurohormonal, and clinical effects consistent with those expected after interference with the renin-angiotensin system" similar to ACE inhibitors 3.
Common Pitfalls to Avoid
Don't assume ACE inhibitors are superior based on older evidence: While ACE inhibitors have longer-standing placebo-controlled trial data, head-to-head comparisons show no mortality or morbidity advantage over ARBs 4, 1
Don't overlook the tolerability advantage: The 17% reduction in treatment discontinuation with ARBs is clinically meaningful for long-term adherence 1
Don't use both together routinely: Combining ACE inhibitors and ARBs increases risks of hypotension, hyperkalemia, and worsening renal function without clear additional benefit in most patients 5, 6, 7
Shared Precautions (Both Classes)
Both ARBs and ACE inhibitors require the same monitoring and caution for:
- Low systemic blood pressure 2, 3
- Renal insufficiency 2, 3
- Elevated serum potassium (>5.0 mEq/L) 2, 3
- Pregnancy (both are contraindicated) 3
Bottom Line
ARBs offer equivalent cardiovascular and renal protection to ACE inhibitors but with a demonstrably better safety profile, particularly regarding cough (the most common side effect) and angioedema (the most serious side effect). Recent evidence suggests ARBs should be considered preferred first-line agents rather than merely alternatives for ACE inhibitor-intolerant patients 8, 4.